Anthem Biosciences Q4 FY26 Results: PAT Rs 189.8 Cr

Anthem Biosciences Q4 FY26 results were declared on May 19, 2026. Anthem Biosciences reported PAT of Rs 189.8 crore for the quarter ended March 31, 2026, on revenue of Rs 610.9 crore for the quarter ended March 31, 2026. Anthem Biosciences is a CRDMO Pharma company listed on Indian stock exchanges. This article covers the complete Anthem Biosciences Q4 FY26 financial highlights, key performance factors, and FY27 outlook for investors tracking Anthem Biosciences.

Click Here – Get Free Investment Predictions

Anthem Biosciences Q4 FY26 Financial Highlights

Note: FY26 annual revenue Rs 2,124 crore, PAT Rs 591.8 crore. Fully integrated CRDMO.

Anthem Biosciences Q4 FY26 Performance Analysis

The Anthem Biosciences Q4 FY26 results reflect Anthem Biosciences’s operational performance during the January to March 2026 quarter. The company operates in the CRDMO Pharma space, a sector supported by India’s strong GDP growth and domestic demand. The Q4 FY26 results demonstrate continued business execution and operational resilience.

Screen the best stocks on the Univest Screener.

Investors tracking Anthem Biosciences Q4 FY26 will focus on FY27 revenue guidance, margin trajectory, and management’s capital allocation commentary. Track Anthem Biosciences on the Univest Screener for live fundamentals and real-time updates.

Key Business Factors for Anthem Biosciences Q4 FY26

Revenue and Operational Performance

Anthem Biosciences Q4 FY26 performance reflects the January to March 2026 quarter, historically the year-end quarter with strong order execution and seasonality effects. India’s macroeconomic environment with GDP growth above 6.5% provided a constructive backdrop for the CRDMO Pharma sector during this period.

Profitability and Margin Trends

the company PAT of Rs 189.8 crore for the quarter ended March 31, 2026. Sustaining profitability and improving operating margins will be key watchpoints for FY27 performance.

India Economic Context for Anthem Biosciences

The January to March 2026 quarter saw strong domestic consumption, fiscal year-end capital expenditure cycles, and government infrastructure spending. The Reserve Bank of India’s supportive monetary stance and India’s resilient growth trajectory provided a stable environment for listed companies across sectors. For Anthem Biosciences, operating in the CRDMO Pharma space, this macro backdrop supported demand conditions during the quarter.

FY27 Outlook and Growth Drivers

Following the listed company results, management commentary on FY27 revenue guidance, capex plans, and order pipeline will be the primary catalysts for investor sentiment. The CRDMO Pharma sector continues to benefit from India’s structural growth, rising domestic consumption, and government policy support.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the group

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.